|
Post by mango on Apr 15, 2020 16:02:57 GMT -5
the investor call page has the new MNKD website look. More Humnann. Thank you for the link. The welcome. MC: employees, keep employees safe. plant running. 4 different COVID 19 opputunites. expect 25 million from UTHR. PPL program.1% two year maturity. reassuring us for 2020. two anti virals two anti infectives. what are the covid19 opps? all with immix? Slides? I can't see any slides
|
|
|
Post by mnkdorbust on Apr 15, 2020 16:08:50 GMT -5
the investor call page has the new MNKD website look. More Humnann. Thank you for the link. The welcome. MC: employees, keep employees safe. plant running. 4 different COVID 19 opputunites. expect 25 million from UTHR. PPL program.1% two year maturity. reassuring us for 2020. two anti virals two anti infectives. MC also mentioned between 20% salary cut's + decrease in expenses would equate to saving roughly 10 million.
|
|
|
Post by centralcoastinvestor on Apr 15, 2020 16:10:44 GMT -5
The welcome. MC: employees, keep employees safe. plant running. 4 different COVID 19 opputunites. expect 25 million from UTHR. PPL program.1% two year maturity. reassuring us for 2020. two anti virals two anti infectives. what are the covid19 opps? all with immix? Slides? I can't see any slides I don’t believe there were slides this time.
|
|
|
Post by mango on Apr 15, 2020 16:15:33 GMT -5
The welcome. MC: employees, keep employees safe. plant running. 4 different COVID 19 opputunites. expect 25 million from UTHR. PPL program.1% two year maturity. reassuring us for 2020. two anti virals two anti infectives. MC also mentioned between 20% salary cut's + decrease in expenses would equate to saving roughly 10 million. Wow. Excellent savings. That equates to around a full quarter in cash burn that we will save correct? 👏
|
|
|
Post by mango on Apr 15, 2020 16:17:30 GMT -5
what are the covid19 opps? all with immix? Slides? I can't see any slides I don’t believe there were slides this time. Who are the other 3 covid-19 opportunities with? I missed the entire call except for analysts q&a
|
|
|
Post by centralcoastinvestor on Apr 15, 2020 16:20:54 GMT -5
Some interesting tidbits I took from the call:
1. He is confident about funding for 2020. (My comment: in a sense, MannKind already went through our money crisis and were prepared for not having to raise funding in 2020. Thus the Covid-19 crisis is manageable for the company. Mike’s Christmas dilution doesn’t look so bad to me now.)
2. He mentioned that work on the PEDS trial has slowed as this is not a high priority right now for the FDA for obvious reasons. What caught my attention was when he said that when the PEDS trial does begin, that there are potentially one or two partners that will help fund the trial. 3. Steady as she goes for TreT
4. Of the 4 novel Covid-19 treatments in development with other partners, 3 are viable with the 4th probably being ended soon. The research on these is costing next to nothing at this point. (My comment: if only we could get 1 to hit. That would change things.)
5. Expect a slowdown in weekly prescription counts for Afrezza for the 2nd quarter. For obvious Covid-19 reasons.
Overall, I thought it was a good conference call with greater participation from analysts than I was expecting.
|
|
|
Post by mango on Apr 15, 2020 16:23:33 GMT -5
Some interesting tidbits I took from the call: 1. He is confident about funding for 2020. (My comment: in a sense, MannKind already went through our money crisis and were prepared for not having to raise funding in 2020. Thus the Covid-19 crisis is manageable for the company. Mike’s Christmas dilution doesn’t look so bad to me now.) 2. He mentioned that work on the PEDS trial has slowed as this is not a high priority right now for the FDA for obvious reasons. What caught my attention was when he said that when the PEDS trial does begin, that there are potentially one or two partners that will help fund the trial. 3. Steady as she goes for TreT 4. Of the 4 novel Covid-19 treatments in development with other partners, 3 are viable with the 4th probably being ended soon. The research on these is costing next to nothing at this point. (My comment: if only we could get 1 to hit. That would change things.) 5. Expect a slowdown in weekly prescription counts for Afrezza for the 2nd quarter. For obvious Covid-19 reasons. Overall, I thought it was a good conference call with greater participation from analysts than I was expecting. Who are all the partners for the covid-19 treatments?
|
|
|
Post by centralcoastinvestor on Apr 15, 2020 16:27:55 GMT -5
Some interesting tidbits I took from the call: 1. He is confident about funding for 2020. (My comment: in a sense, MannKind already went through our money crisis and were prepared for not having to raise funding in 2020. Thus the Covid-19 crisis is manageable for the company. Mike’s Christmas dilution doesn’t look so bad to me now.) 2. He mentioned that work on the PEDS trial has slowed as this is not a high priority right now for the FDA for obvious reasons. What caught my attention was when he said that when the PEDS trial does begin, that there are potentially one or two partners that will help fund the trial. 3. Steady as she goes for TreT 4. Of the 4 novel Covid-19 treatments in development with other partners, 3 are viable with the 4th probably being ended soon. The research on these is costing next to nothing at this point. (My comment: if only we could get 1 to hit. That would change things.) 5. Expect a slowdown in weekly prescription counts for Afrezza for the 2nd quarter. For obvious Covid-19 reasons. Overall, I thought it was a good conference call with greater participation from analysts than I was expecting. Who are all the partners for the covid-19 treatments? He didn’t say. But he also mentioned that although they are not directly working on a vaccine, Technosphere is a still plausible delivery system. So they are open to delivering a vaccine if called upon to do so.
|
|
|
Post by mango on Apr 15, 2020 16:32:38 GMT -5
Who are all the partners for the covid-19 treatments? He didn’t say. But he also mentioned that although they are not directly working on a vaccine, Technosphere is a still plausible delivery system. So they are open to delivering a vaccine if called upon to do so. That's rather odd to not disclose who we are partnered with... Did he give a timeline for their development? If 3 are viable when will we start animal studies and human clinical trials?
|
|
|
Post by mango on Apr 15, 2020 16:54:06 GMT -5
The only significant and really positive thing about today is we are going to save approximately a full quarter's worth of cash burn from the pay cuts.
Everything else was just noise, IMO.
Doesn't seem like halting the pipeline exclusively for COVID-19 treatments is justified. Or am I missing something?
If we can get just one of them fully developed then I suppose it will be, but when investors are left in the dark about what is actually being done, and with who, it leaves little in terms of confidence .
|
|
|
Post by majorwood on Apr 15, 2020 17:02:28 GMT -5
Great work Mike C. Keep up the fight. MNKD will be huge winner, come hell or high water and I think we've seen them all and more.
Good luck and stay safe
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2020 18:33:01 GMT -5
The only significant and really positive thing about today is we are going to save approximately a full quarter's worth of cash burn from the pay cuts. Everything else was just noise, IMO. Doesn't seem like halting the pipeline exclusively for COVID-19 treatments is justified. Or am I missing something? If we can get just one of them fully developed then I suppose it will be, but when investors are left in the dark about what is actually being done, and with who, it leaves little in terms of confidence . Can you break down and display those numbers?? I don't see $12M in savings from salary cuts.
|
|
|
Post by cjm18 on Apr 15, 2020 18:39:21 GMT -5
The only significant and really positive thing about today is we are going to save approximately a full quarter's worth of cash burn from the pay cuts. Everything else was just noise, IMO. Doesn't seem like halting the pipeline exclusively for COVID-19 treatments is justified. Or am I missing something? If we can get just one of them fully developed then I suppose it will be, but when investors are left in the dark about what is actually being done, and with who, it leaves little in terms of confidence . Can you break down and display those numbers?? I don't see $12M in savings from salary cuts. I recall from the update that it was 10m from the loan, salary reductions, and other expenses.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2020 18:42:54 GMT -5
Can you break down and display those numbers?? I don't see $12M in savings from salary cuts. I recall from the update that it was 10m from the loan, salary reductions, and other expenses. OK let's use $10M....I don't see how Mango gets to that number.
|
|
|
Post by itellthefuture777 on Apr 15, 2020 19:13:49 GMT -5
I recall from the update that it was 10m from the loan, salary reductions, and other expenses. OK let's use $10M....I don't see how Mango gets to that number. pay cuts...
|
|